Eric Richman
Director/Board Member at GAIN THERAPEUTICS, INC.
Net worth: 922 273 $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Dov Goldstein | M | 56 |
ADMA Plasma Biologics, Inc.
 ADMA Plasma Biologics, Inc. BiotechnologyHealth Technology ADMA Plasma Biologics, Inc. develops medicines for the treatment of infectious diseases. The company was founded in 2007 and is headquartered in Hackensack, NJ. | 17 years |
| Tim Johnson | M | - |
InFUSE Holdings, Inc.
 InFUSE Holdings, Inc. Medical/Nursing ServicesHealth Services InFUSE Holdings, Inc. owns and operates ambulatory infusion centers. The company was founded by Timothy P. Johnson, Eric I. Richman, David M. Rothenberg, Gregory Gottschlich and is headquartered in Bethesda, MD.
LabConnect, Inc.
 LabConnect, Inc. Medical/Nursing ServicesHealth Services Labconnect LLC provides global central laboratory services. It offers routine and esoteric laboratory testing, kit building, sample management, biorepository and scientific support services. The company serves biopharmaceutical, medical device and contract research organizations. Labconnect was founded by Jeff Mayhew in 2002 and is headquartered in Seattle, WA. | 7 years |
| Mitchell Rubenstein | M | 70 | 31 years | |
| Matthias Alder | M | 59 | 3 years | |
| Todd Branning | M | 54 | 2 years | |
| Kaitlin Kestenberg | F | 37 | 13 years | |
| Steven Elms | M | 60 | 17 years | |
| Gianluca Fuggetta | M | 35 | 2 years | |
| Joshua Weiyuan Wang | M | - |
Verimmune, Inc.
 Verimmune, Inc. BiotechnologyHealth Technology Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then. | - |
| Alain Chetrit | M | - |
Labconnect Holdings, Inc.
 Labconnect Holdings, Inc. Medical/Nursing ServicesHealth Services Labconnect Holdings, Inc. engages in providing laboratory services which include routine and esoteric laboratory testing, kit building, sample management, biorepository and scientific support services for biopharmaceutical. The company is headquartered in Seattle, WA.
LabConnect, Inc.
LabConnect, Inc. Medical/Nursing ServicesHealth Services Labconnect LLC provides global central laboratory services. It offers routine and esoteric laboratory testing, kit building, sample management, biorepository and scientific support services. The company serves biopharmaceutical, medical device and contract research organizations. Labconnect was founded by Jeff Mayhew in 2002 and is headquartered in Seattle, WA. | - |
| Claude Nicaise | M | 71 | 3 years | |
| David M. Rothenberg | M | - |
InFUSE Holdings, Inc.
InFUSE Holdings, Inc. Medical/Nursing ServicesHealth Services InFUSE Holdings, Inc. owns and operates ambulatory infusion centers. The company was founded by Timothy P. Johnson, Eric I. Richman, David M. Rothenberg, Gregory Gottschlich and is headquartered in Bethesda, MD. | - |
| Gerald McDougall | M | 57 | 3 years | |
| Dawn Sherman | F | 57 |
LabConnect, Inc.
LabConnect, Inc. Medical/Nursing ServicesHealth Services Labconnect LLC provides global central laboratory services. It offers routine and esoteric laboratory testing, kit building, sample management, biorepository and scientific support services. The company serves biopharmaceutical, medical device and contract research organizations. Labconnect was founded by Jeff Mayhew in 2002 and is headquartered in Seattle, WA. | 2 years |
| Solomon Langermann | M | 64 |
PharmAthene, Inc.
 PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD.
Verimmune, Inc.
Verimmune, Inc. BiotechnologyHealth Technology Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then. | 4 years |
| Khalid Islam | M | 67 | 7 years | |
| John Troyer | M | - |
Verimmune, Inc.
Verimmune, Inc. BiotechnologyHealth Technology Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then. | - |
| Manolo Bellotto | M | 53 | 6 years | |
| Christine Jenkins | F | 61 | 2 years | |
| Hans-Peter Hasler | M | 68 | 3 years | |
| John David Stobo | M | - |
Labconnect Holdings, Inc.
Labconnect Holdings, Inc. Medical/Nursing ServicesHealth Services Labconnect Holdings, Inc. engages in providing laboratory services which include routine and esoteric laboratory testing, kit building, sample management, biorepository and scientific support services for biopharmaceutical. The company is headquartered in Seattle, WA.
LabConnect, Inc.
LabConnect, Inc. Medical/Nursing ServicesHealth Services Labconnect LLC provides global central laboratory services. It offers routine and esoteric laboratory testing, kit building, sample management, biorepository and scientific support services. The company serves biopharmaceutical, medical device and contract research organizations. Labconnect was founded by Jeff Mayhew in 2002 and is headquartered in Seattle, WA. | - |
| Gwen Melincoff | M | 72 | 3 years | |
| Lawrence Guiheen | M | 73 | 12 years | |
| Jan Loeb | M | 64 | 6 years | |
| Jeffrey Riley | M | 61 | 5 years | |
| David Seltzer | M | 64 | - | |
| Shannon McCarthy | F | - | - | |
| Cynthia Poa | F | - |
Verimmune, Inc.
Verimmune, Inc. BiotechnologyHealth Technology Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then. | - |
| Elena Cubero-Jorda | F | - | - | |
| Alan Scrivner | M | - | 3 years | |
| Ron Sarkar | M | - | 3 years | |
| Kevin Koh | M | - |
Verimmune, Inc.
Verimmune, Inc. BiotechnologyHealth Technology Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then. | - |
| Mark Anderson | M | - |
LabConnect, Inc.
LabConnect, Inc. Medical/Nursing ServicesHealth Services Labconnect LLC provides global central laboratory services. It offers routine and esoteric laboratory testing, kit building, sample management, biorepository and scientific support services. The company serves biopharmaceutical, medical device and contract research organizations. Labconnect was founded by Jeff Mayhew in 2002 and is headquartered in Seattle, WA. | - |
| Drew Pantello | M | - | 6 years | |
| Cynthia R. Tolman | F | - |
ADMA Plasma Biologics, Inc.
ADMA Plasma Biologics, Inc. BiotechnologyHealth Technology ADMA Plasma Biologics, Inc. develops medicines for the treatment of infectious diseases. The company was founded in 2007 and is headquartered in Hackensack, NJ. | - |
| Gregory M. Gottschlich | M | - |
InFUSE Holdings, Inc.
InFUSE Holdings, Inc. Medical/Nursing ServicesHealth Services InFUSE Holdings, Inc. owns and operates ambulatory infusion centers. The company was founded by Timothy P. Johnson, Eric I. Richman, David M. Rothenberg, Gregory Gottschlich and is headquartered in Bethesda, MD. | - |
| Jerry Wolasky | M | - | - | |
| Myron Murdock | M | - |
Labconnect Holdings, Inc.
Labconnect Holdings, Inc. Medical/Nursing ServicesHealth Services Labconnect Holdings, Inc. engages in providing laboratory services which include routine and esoteric laboratory testing, kit building, sample management, biorepository and scientific support services for biopharmaceutical. The company is headquartered in Seattle, WA. | - |
| Sam Osman | M | - |
LabConnect, Inc.
LabConnect, Inc. Medical/Nursing ServicesHealth Services Labconnect LLC provides global central laboratory services. It offers routine and esoteric laboratory testing, kit building, sample management, biorepository and scientific support services. The company serves biopharmaceutical, medical device and contract research organizations. Labconnect was founded by Jeff Mayhew in 2002 and is headquartered in Seattle, WA. | - |
| Roger Pomerantz | M | 67 |
Verimmune, Inc.
Verimmune, Inc. BiotechnologyHealth Technology Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then. | - |
| Adam Grossman | M | 47 |
ADMA Plasma Biologics, Inc.
ADMA Plasma Biologics, Inc. BiotechnologyHealth Technology ADMA Plasma Biologics, Inc. develops medicines for the treatment of infectious diseases. The company was founded in 2007 and is headquartered in Hackensack, NJ. | - |
| Jack Henriques | M | - |
ADMA Plasma Biologics, Inc.
ADMA Plasma Biologics, Inc. BiotechnologyHealth Technology ADMA Plasma Biologics, Inc. develops medicines for the treatment of infectious diseases. The company was founded in 2007 and is headquartered in Hackensack, NJ. | - |
| Stephen L. Collins | M | - |
Lev Pharmaceuticals, Inc.
 Lev Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lev Pharmaceuticals, Inc. develops and commercializes therapeutic products for the treatment of inflammatory diseases. It researches a series of drugs to fight both edema and heart attacks. The company is located in New York. | 17 years |
| Tracy Clifford | F | 55 | 6 years | |
| Robert Finizio | M | 53 |
ZyVersa Therapeutics Operating, Inc.
 ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL. | 6 years |
| Bryant Fong | M | 51 | 12 years | |
| Mark Steven Anderson | M | 66 |
Labconnect Holdings, Inc.
Labconnect Holdings, Inc. Medical/Nursing ServicesHealth Services Labconnect Holdings, Inc. engages in providing laboratory services which include routine and esoteric laboratory testing, kit building, sample management, biorepository and scientific support services for biopharmaceutical. The company is headquartered in Seattle, WA. | - |
| Marc S. Gelberg | M | 58 | 7 years | |
| Dani Stoltzfus | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Dietrich Stephan | M | 54 | 15 years | |
| Jeff Jones | M | 52 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 10 years |
| Mack Gill | M | 72 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 10 years |
| Philip MacNeill | M | 70 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | - |
| Mitchel Sayare | M | 76 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | - |
| Samuel Backenroth | M | 39 | 2 years | |
| Arnold Kling | M | 66 | - | |
| Douglas Beck | M | 62 |
Lev Pharmaceuticals, Inc.
Lev Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lev Pharmaceuticals, Inc. develops and commercializes therapeutic products for the treatment of inflammatory diseases. It researches a series of drugs to fight both edema and heart attacks. The company is located in New York. | 4 years |
| Christopher C. Camut | M | 61 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | - |
| Salvatore Calabrese | M | 54 | 3 years | |
| Linda L. Chang | F | 57 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 4 years |
| Joel W. McCleary | M | 75 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 8 years |
| Joseph Truitt | M | 59 |
Lev Pharmaceuticals, Inc.
Lev Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lev Pharmaceuticals, Inc. develops and commercializes therapeutic products for the treatment of inflammatory diseases. It researches a series of drugs to fight both edema and heart attacks. The company is located in New York. | 2 years |
| William Mann | M | 63 | 2 years | |
| Franklyn Prendergast | M | 79 | - | |
| Derace L. Schaffer | M | 76 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | - |
| J. Stark Thompson | M | 82 | 20 years | |
| Jeffrey Runge | M | 67 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | - |
| Jordan P. Karp | M | 57 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 6 years |
| Charles Ballantyne | M | 64 | 1 years | |
| Brian Lenz | M | 51 | 12 years | |
| Brian Markison | M | 64 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 4 years |
| Judson A. Cooper | M | 65 |
Lev Pharmaceuticals, Inc.
Lev Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lev Pharmaceuticals, Inc. develops and commercializes therapeutic products for the treatment of inflammatory diseases. It researches a series of drugs to fight both edema and heart attacks. The company is located in New York. | - |
| Steven St. Peter | M | 57 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | - |
| Kevin Connolly | M | - |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | - |
| John Pappajohn | M | 96 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 4 years |
| James Mond | M | 77 | 9 years | |
| James Hauert | M | - | 2 years | |
| Linda N. Liu | M | 57 | 7 years | |
| Theresa Gwaltney | F | - | 3 years | |
| Jeffrey Steinberg | M | - |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | - |
| Ayelet Dilion-Mashiah | F | - | 7 years | |
| Mathew Peters | M | - | - | |
| Adam Pinkert | M | - | - | |
| Doris Connell | M | - | 1 years | |
| Joan Fusco | M | 68 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | - |
| Charles Reinhart | M | 63 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 2 years |
| Lorenzo Leoni | M | - | 4 years | |
| Henry M. Dachowitz | M | - |
Lev Pharmaceuticals, Inc.
Lev Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lev Pharmaceuticals, Inc. develops and commercializes therapeutic products for the treatment of inflammatory diseases. It researches a series of drugs to fight both edema and heart attacks. The company is located in New York. | 1 years |
| Wayne Morges | M | 76 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 8 years |
| Francesca M. Cook | F | 58 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 12 years |
| Wayne A. Schellhammer | M | 70 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 2 years |
| Edward B. Berger | M | 95 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 2 years |
| Elizabeth Czerepak | F | 58 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 4 years |
| David P. Wright | M | 75 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 3 years |
| Thomas Lanier | M | - |
Lev Pharmaceuticals, Inc.
Lev Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lev Pharmaceuticals, Inc. develops and commercializes therapeutic products for the treatment of inflammatory diseases. It researches a series of drugs to fight both edema and heart attacks. The company is located in New York. | 4 years |
| Thomas R. Fuerst | M | 67 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 2 years |
| Ronald W. Kaiser | M | 70 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 1 years |
| James Cavanaugh | M | 87 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 4 years |
| Marc A. Cohen | M | 61 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 1 years |
| Anthony Rossomando | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Eric Richman
- Personal Network
